06 / About Clinaptis
Independent
by design.
Clinaptis is an independent biopharma research platform built to examine the gap between reported evidence, market expectations and investment outcomes.
Research philosophy
The conclusion matters.
The variables matter more.
- 01Reconstruct the evidence
Normalize trials, endpoints and populations before comparing the headline.
- 02Make expectations explicit
Ask what the valuation and prevailing narrative already appear to assume.
- 03Define what changes the view
Separate conviction from certainty through auditable assumptions and sensitivities.
Founder & editor
Bikram K. Singh, MBBS
Bikram K. Singh, MBBS, is the founder and editor of Clinaptis. He brings together a medical background with buy-side hedge fund and sell-side equity research experience. His work focuses on clinical-trial interpretation, market expectations and valuation across public biopharma—particularly where a headline result obscures the variables that determine the investment outcome.
Clinaptis grew from independent published research and a conviction that rigorous judgment becomes more useful when its evidence, assumptions and failure conditions are visible.
Contact